1 min read
ASH Annual Meeting and Exposition
Meet Veristat at ASH Meeting and Exposition December 6-9, 2025
Veristat is excited to attend the ASH Annual Meeting and...
1 min read
Learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas of this full-service phase II cancer trial. Collaborative efforts led to the sponsor decided not to close the Phase II study upon the recommendation of the Safety Review Committee since the primary endpoint was met and there were no safety concerns.
A clinical-stage biopharmaceutical company approached Veristat in a multi-center, randomized Phase II study of a modified synthetic peptide in patients with exocrine pancreatic cancer. The study aimed to establish the efficacy and safety of combinations of the therapy in patients with stage IV exocrine pancreatic cancer.
In this piece, learn how Veristat’s multidisciplinary team was able to work with the sponsor to solve challenges across numerous areas including:
Meet Veristat. Learn More.
1 min read
Oct 22, 2025 Veristat Events
Veristat is excited to attend the ASH Annual Meeting and...
2 min read
Oct 17, 2025 Veristat Events
Veristat is proud to participate...